Depression impacts visual function

Article

Depression in retinitis pigmentosa (RP) patients worsens vision-related function even where visual acuity is not compromised, according to a study published in the May 2008 issue of the British Journal of Ophthalmology.

Depression in retinitis pigmentosa (RP) patients worsens vision-related function even where visual acuity is not compromised, according to a study published in the May 2008 issue of the British Journal of Ophthalmology.

Professor H Gon Yu of the Department of Ophthalmology, Seoul National University College of Medicine, Korea and colleagues gave 144 RP patients the National Eye Institute Visual Function Questionnaire (NEI-VFQ) to evaluate vision-related quality of life and the Beck Depression Inventory (BDI) to assess symptoms of depression.

Based on BDI score, patients were categorized into two groups, depressed and non-depressed, and NEI-VFQ composite and subscale scores were compared between groups. The researchers found that, regardless of actual visual acuity or function, depressed patients had worse subjective visual function than non-depressed patients.

The lack of correlation between NEI-VFQ and BDI scores indicated to the researchers that depression has no impact on visual acuity in RP patients but that vision-related functions are decreased in depressed subjects; the researchers concluded that diagnosing and treating depression would improve quality of life for RP patients.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.